Bioprocess Development !free! - A Mab A Case Study In

: It defines CQAs (e.g., aggregates, galactosylation, and host cell protein) and uses a "Continuum of Criticality" to rank their impact on safety and efficacy.

The is a landmark industry document developed by the CMC Biotech Working Group to demonstrate how Quality by Design (QbD) principles can be applied to the development and manufacturing of a monoclonal antibody (mAb). Released in 2009, it serves as a comprehensive roadmap for navigating the complex journey from laboratory discovery to large-scale commercial production. Core Objectives of the A-Mab Study A Mab A Case Study In Bioprocess Development

To ensure safety, the eluate undergoes low-pH viral inactivation (pH 3.6 for 90 minutes). For Mab-X, which is moderately acid-labile, the team adds 100 mM sodium acetate as a stabilizing excipient during this step. Post-inactivation, pH is raised to 5.5 using 2M Tris base. Analytical data confirm >4 log reduction of model viruses (xMuLV) without compromising product quality. : It defines CQAs (e